论文信息 - A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib. - 字舞流文

A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib.

A. Ballestrero | F. Patrone | E. Moran | M. Gobbi | N. Colombo | A. Nencioni | G. Cirmena | A. Garuti | M. Cea | I. Rocco | G. Fugazza | R. Grasso | C. Palermo | A. Cagnetta

[1] S. Olschwang,et al. Y253H mutation appearing in a μ-BCR-ABL (e19a2) CML , 2008 .

[2] J. Melo,et al. Chronic myeloid leukemia--advances in biology and new approaches to treatment. , 2003, The New England journal of medicine.

[3] H. Kantarjian,et al. Neutrophilic‐chronic myeloid leukemia , 2002, Cancer.

[4] J. Melo,et al. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. , 1996, Blood.

[5] G. Meloni,et al. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction) , 1996, Blood.

[6] E. L. Tuohy. A CASE OF SPLENOMEGALY WITH POLYMORPHONUCLEAR NEUTROPHIL HYPERLEUKOCYTOSIS , 1920 .